The anti-Tissue factor pathway inhibitor antibody detected positive in western blot analysis of TFPI in A549, HL-60, U2OS lysates. The recombinant monoclonal antibody has been meticulously designed to target human TFPI. It is suitable for use in a variety of assays, including WB, IP. This R07-6A6 antibody is validated for western blot analysis of TFPI in A549, HL-60, U2OS lysates.
Figure 1 Anti-TFPI Antibody (VS3-FY2092) in WB.
The TFPI expression in A549, HL-60, U2OS lysates were detected using the anti-TFPI by western blot assay.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-734 | Anti-TFPI Recombinant Antibody (Concizumab) | ELISA, IP, FC, FuncS, Neut, IF, WB | IgG4 - kappa |
There are currently no Customer reviews or questions for VS3-FY2092. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.